PCSK9 doesn't just affect cholesterol—it also turns on inflammation switches in immune cells, which can damage blood vessels even if cholesterol is normal.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Determine if PCSK9 inhibition reduces inflammatory biomarkers in humans.
A double-blind RCT of 500 patients with elevated hsCRP and LDL-C, randomized to alirocumab vs placebo for 24 weeks, measuring changes in IL-6, TNF-α, and hsCRP, with adjustment for LDL-C change.
Assess association between PCSK9 levels and inflammatory markers in population studies.
A prospective cohort of 10,000 adults free of CVD at baseline, measuring baseline PCSK9, LDL-C, and hsCRP, followed for 5 years for incident CVD and change in inflammatory markers.
Compare PCSK9 and inflammation markers in patients with vs without acute vascular events.
A case-control study of 200 patients with recent MI vs 200 matched controls, measuring plasma PCSK9, TLR4 expression on monocytes, and NF-κB activity in isolated cells.
Illustrate potential clinical links between PCSK9, inflammation, and disease.
A case series of 5 patients with sepsis and extremely high PCSK9 levels, documenting serial inflammatory markers, organ function, and response to PCSK9 inhibitor if used.